MCID: PMP001
MIFTS: 54

Pemphigus

Categories: Rare diseases, Skin diseases, Genetic diseases

Aliases & Classifications for Pemphigus

MalaCards integrated aliases for Pemphigus:

Name: Pemphigus 12 76 53 37 55 43 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9182
ICD10 33 L10 L10.9
ICD9CM 35 694.4
MeSH 44 D010392
NCIt 50 C34909
KEGG 37 H01648
UMLS 73 C0030807

Summaries for Pemphigus

NIH Rare Diseases : 53 Pemphigus is a group of rare autoimmune diseases that cause blistering of the skin and mucous membranes (mouth, nose, throat, eyes, and genitals). This condition can occur at any age, but often strikes people in middle or older age. Studies have shown that some populations may be at greater risk for certain types of pemphigus. For instance, people of Jewish descent and those from India, Southeast Europe, and the Middle East are at greater risk for pemphigus vulargis, while pemphigus foliaceus is more common in North America, Turkey, and South America. Pemphigus is a chronic disease which is best controlled by early diagnosis and treatment. Treatment includes steroids to reduce inflammation, drugs that suppress the immune system response and antibiotics to treat associated infections. There are four main types of pemphigus: Pemphigus vulgaris Pemphigus foliaceus IgA pemphigus Paraneoplastic pemphigus

MalaCards based summary : Pemphigus is related to pemphigus erythematosus and pemphigus vegetans, and has symptoms including exanthema and pruritus. An important gene associated with Pemphigus is DSG3 (Desmoglein 3), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs rituximab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

MedlinePlus : 43 Pemphigus is an autoimmune disorder. If you have it, your immune system attacks healthy cells in your skin and mouth, causing blisters and sores. No one knows the cause. Pemphigus does not spread from person to person. It does not appear to be inherited. But some people's genes put them more at risk for pemphigus. Pemphigoid is also an autoimmune skin disease. It leads to deep blisters that do not break easily. Pemphigoid is most common in older adults and may be fatal for older, sick patients. Doctors diagnose pemphigus with a physical exam, a biopsy, and blood tests. The treatment of pemphigus and pemphigoid is the same: one or more medicines to control symptoms. These may include Steroids, which reduce inflammation Drugs that suppress the immune system response Antibiotics to treat associated infections NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Wikipedia : 76 Pemphigus (/ˈpɛmfɪɡəs/ or /pɛmˈfaɪɡəs/) is a rare group of blistering autoimmune diseases that affect... more...

Related Diseases for Pemphigus

Diseases in the Pemphigus family:

Benign Chronic Pemphigus

Diseases related to Pemphigus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 317)
# Related Disease Score Top Affiliating Genes
1 pemphigus erythematosus 34.9 DSG3 DSP
2 pemphigus vegetans 34.4 DSC3 DSG1 PPL
3 benign chronic pemphigus 34.3 ATP2C1 DSP JUP
4 herpetiform pemphigus 33.7 DSG1 DSG3 DST
5 ritter's disease 32.6 DSG1 DSG2 DSG4
6 pemphigus foliaceus 32.3 DSG1 DSG2 DSG3 DST EVPL PPL
7 epidermolysis bullosa, lethal acantholytic 32.1 DSP JUP
8 cicatricial pemphigoid 31.4 CD79A COL17A1 DST
9 bullous impetigo 31.0 DSG1 DSG3
10 follicular dendritic cell sarcoma 30.8 DSP EVPL PPL
11 pemphigus vulgaris 30.2 DSC3 DSG1 DSG2 DSG3 DSG4 DSP
12 grover's disease 30.1 DSP JUP
13 darier-white disease 29.7 ATP2C1 DSP JUP
14 linear iga disease 29.7 CD79A COL17A1 DST
15 lichen planus 29.5 COL17A1 DSG3 DST
16 hypotrichosis 29.5 DSC3 DSG1 DSG4
17 lichen planus pemphigoides 29.5 COL17A1 DST
18 erythema multiforme 29.3 CD79A DSP
19 pemphigoid gestationis 29.2 COL17A1 DST
20 herpes gestationis 29.1 COL17A1 DST
21 bullous pemphigoid 29.0 CD79A COL17A1 DSG1 DSG3 DSP DST
22 epidermolysis bullosa 28.4 COL17A1 DSP DST
23 paraneoplastic pemphigus 28.4 A2ML1 COL17A1 DSC1 DSC3 DSG1 DSG2
24 subcorneal pustular dermatosis 26.1 CD79A COL17A1 DSC1 DSC3 DSG1 DSG3
25 skin disease 25.4 ATP2C1 CD79A COL17A1 DSC1 DSC3 DSG1
26 bullous skin disease 25.0 ATP2C1 CD79A COL17A1 DSC3 DSG1 DSG3
27 pemphigus vulgaris, familial 12.5
28 pemphigus and fogo selvagem 12.2
29 brunsting-perry syndrome 10.9
30 recessive dystrophic epidermolysis bullosa-generalized other 10.9
31 erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper-ige 10.8 DSG1 DSP
32 striate palmoplantar keratoderma 10.6 DSG1 DSP
33 cardiomyopathy, dilated, with woolly hair and keratoderma 10.5 DSP JUP
34 palmoplantar keratoderma and woolly hair 10.5 DSP JUP
35 naxos disease 10.5 DSP JUP
36 ectodermal dysplasia/skin fragility syndrome 10.4 DSP JUP
37 nodular malignant melanoma 10.4 DSG1 DSG3
38 arrhythmogenic right ventricular dysplasia, familial, 9 10.4 DSP JUP
39 arrhythmogenic right ventricular dysplasia, familial, 8 10.4 DSP JUP
40 palmoplantar keratosis 10.3 DSG1 DSP JUP
41 lymphoma 10.3
42 mucositis 10.2
43 sarcoma 10.2
44 thymoma 10.2
45 psoriasis 10.2
46 bronchiolitis 10.1
47 lupus erythematosus 10.1
48 bronchiolitis obliterans 10.1
49 myasthenia gravis 10.1
50 myasthenia gravis congenital 10.1

Comorbidity relations with Pemphigus via Phenotypic Disease Network (PDN):


Acute Cystitis Bullous Pemphigoid
Decubitus Ulcer Heart Disease

Graphical network of the top 20 diseases related to Pemphigus:



Diseases related to Pemphigus

Symptoms & Phenotypes for Pemphigus

UMLS symptoms related to Pemphigus:


exanthema, pruritus

GenomeRNAi Phenotypes related to Pemphigus according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.58 CD79A DSG4
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.58 A2ML1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.58 A2ML1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.58 ATP2C1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 9.58 A2ML1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.58 A2ML1 ATP2C1 CD79A DSG4
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 9.58 DSG4
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.58 ATP2C1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.58 ATP2C1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.58 DSG4
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.58 A2ML1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.58 A2ML1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.58 ATP2C1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.58 A2ML1

MGI Mouse Phenotypes related to Pemphigus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.28 ATP2C1 DSC1 DSC3 DSG1 DSG3 DSG4

Drugs & Therapeutics for Pemphigus

Drugs for Pemphigus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3,Phase 2,Phase 1,Not Applicable 174722-31-7 10201696
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
4
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
5
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
6
Mycophenolic acid Approved Phase 3 24280-93-1 446541
7
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
8
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
9
Prednisone Approved, Vet_approved Phase 3,Phase 2,Early Phase 1 53-03-2 5865
10
Cetirizine Approved Phase 3 83881-51-0 2678
11
Acetaminophen Approved Phase 3 103-90-2 1983
12
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
13 Alkylating Agents Phase 3,Phase 2
14 Gastrointestinal Agents Phase 2, Phase 3,Phase 3,Not Applicable
15 Neurotransmitter Agents Phase 3,Phase 1
16 Antibodies Phase 3,Phase 2,Not Applicable
17 Immunoglobulins Phase 3,Phase 2,Not Applicable
18 Immunosuppressive Agents Phase 3,Phase 2,Early Phase 1
19 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2
21 triamcinolone acetonide Phase 3
22 Prednisolone acetate Phase 3,Phase 2
23 Dexamethasone acetate Phase 2, Phase 3 1177-87-3
24 Analgesics Phase 3,Phase 2
25 glucocorticoids Phase 3,Phase 2
26
protease inhibitors Phase 2, Phase 3
27 Methylprednisolone acetate Phase 3,Phase 2
28 Methylprednisolone Hemisuccinate Phase 3,Phase 2
29 Rho(D) Immune Globulin Phase 3,Phase 2
30 gamma-Globulins Phase 3,Phase 2
31 Analgesics, Non-Narcotic Phase 3,Phase 2
32 HIV Protease Inhibitors Phase 2, Phase 3
33 Hormone Antagonists Phase 3,Phase 2
34 Triamcinolone diacetate Phase 3
35 Triamcinolone hexacetonide Phase 3
36 Hormones Phase 3,Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
38 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3
39 Anti-Bacterial Agents Phase 3,Phase 2,Early Phase 1
40 Antibiotics, Antitubercular Phase 3,Early Phase 1
41 Immunoglobulins, Intravenous Phase 3,Phase 2
42 Antibodies, Monoclonal Phase 3,Phase 2
43 Prednisolone hemisuccinate Phase 3,Phase 2
44 Prednisolone phosphate Phase 3,Phase 2
45 Anti-Infective Agents Phase 3,Phase 2,Early Phase 1
46 Antiemetics Phase 2, Phase 3,Phase 3
47 Anti-Inflammatory Agents Phase 3,Phase 2
48 Antitubercular Agents Phase 3
49 BB 1101 Phase 2, Phase 3
50 Autonomic Agents Phase 2, Phase 3,Phase 3

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus Unknown status NCT01974518 Phase 3 Rituximab and Cyclophosphamide IV
2 Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris Completed NCT02828163 Phase 3 Triamcinolone Acetonide
3 Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus Completed NCT00784589 Phase 3 General Corticotherapy;Rituximab
4 Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab Completed NCT01299857 Phase 3 Rituximab
5 Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris Completed NCT01920477 Phase 3
6 Effect of Anti CD20 in Pemphigus Desease Completed NCT00213512 Phase 2, Phase 3 Mabthera
7 European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus Completed NCT00127764 Phase 2, Phase 3 dexamethasone (50mg 1dd6, 3 consecutive days/month)
8 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV) Completed NCT00683930 Phase 3 Mycophenolate Mofetil 2 g/Day;Mycophenolate Mofetil (MMF) 3 g/Day;Placebo
9 Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Completed NCT01408550 Phase 3 NPB-01;Placebo
10 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Recruiting NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
11 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Active, not recruiting NCT02383589 Phase 3 Mycophenolate Mofetil Placebo;Mycophenolate Mofetil;Rituximab;Rituximab Placebo
12 Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris Terminated NCT02613910 Phase 3 Ofatumumab;Acetaminophen/paracetamol;Antihistamine (cetirizine or equivalent);Prednisone/Prednisolone
13 Use of KC706 for the Treatment of Pemphigus Vulgaris Completed NCT00606749 Phase 2 KC706
14 Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus Completed NCT00656656 Phase 2 Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
15 Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone Completed NCT00626678 Phase 2 Azathioprine;Prednisone;Placebo
16 Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris Completed NCT00135720 Phase 2 Enbrel (Etanercept)
17 Use of Infliximab for the Treatment of Pemphigus Vulgaris Completed NCT00283712 Phase 2 Infliximab
18 Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus Completed NCT00010413 Phase 2 cyclophosphamide;filgrastim
19 Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Completed NCT00809822 Phase 2 NPB-01;Placebo
20 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Completed NCT00584935 Phase 1, Phase 2 Rituximab
21 A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus Recruiting NCT03334058 Phase 2 ARGX-113
22 A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris Recruiting NCT02704429 Phase 2 PRN1008
23 Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris Active, not recruiting NCT01930175 Phase 2 VAY736;Placebo to VAY736;VAY736
24 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus Terminated NCT00483119 Phase 2 intravenous immunoglobulin;cyclophosphamide
25 Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris Terminated NCT00429533 Phase 2 Dapsone
26 Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid Terminated NCT01571895 Phase 2 DF2156A
27 Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Unknown status NCT02782702 Phase 1 Botulism Toxin Treatment
28 Safety Study of PI-0824 to Treat Pemphigus Vulgaris Completed NCT00063752 Phase 1 PI-0824
29 A Safety Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Recruiting NCT03075904 Phase 1 SYNT001
30 Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus Recruiting NCT03239470 Phase 1
31 Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders Terminated NCT00278642 Phase 1
32 Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex Unknown status NCT01338103 Not Applicable Rituximab
33 Wound Dressings for Pemphigus and Pemphigoid Unknown status NCT02365675 Not Applicable
34 National Registry for Ichthyosis and Related Disorders Unknown status NCT00074685
35 Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus Completed NCT00213421 Dermoval
36 Register of Autoimmune Bullous Dermatoses Completed NCT02899923
37 The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders Completed NCT00960713 Rituximab (MABTHERA® or RITUXAN®).
38 Is the Current Threshold for Diagnosis of "Abnormality", Including Non ST Elevation Myocardial Infarction, Using Raised Highly Sensitive Troponin Appropriate for a Hospital Population? The CHARIOT Study Completed NCT03047785
39 Identification of Vulnerability Factors in the Course of Pemphigus Patients Recruiting NCT02237313 Not Applicable
40 Autoimmune Blistering Diseases Study Recruiting NCT02753777
41 Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid Recruiting NCT02874079 Not Applicable
42 Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases Recruiting NCT01952275
43 Serum IL-21 Levels in Patients With Pemphigus Vulgaris Not yet recruiting NCT03177213
44 Trichoscopy in Diagnosis of Immunobollous Diseases Not yet recruiting NCT03478072
45 Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids Not yet recruiting NCT02872584 Prednisone
46 Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus Terminated NCT01313923 Early Phase 1 Sirolimus (formerly known as Rapamycin)
47 Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Terminated NCT01559155

Search NIH Clinical Center for Pemphigus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pemphigus

Genetic Tests for Pemphigus

Anatomical Context for Pemphigus

MalaCards organs/tissues related to Pemphigus:

41
Skin, Testes, T Cells, B Cells, Eye, Neutrophil, Thyroid

Publications for Pemphigus

Articles related to Pemphigus:

(show top 50) (show all 2471)
# Title Authors Year
1
Psoriasiform Pemphigus Foliaceus in an African American Female: An Important Clinical Manifestation. ( 29601624 )
2018
2
New biochip immunofluorescence test for the serological diagnosis of pemphigus vulgaris and foliaceus: A review of the literature. ( 29872685 )
2018
3
Paraneoplastic Pemphigus Associated With Castleman Disease Detected by 18F-FDG PET/CT. ( 29561527 )
2018
4
A case of antiepiligrin cicatricial pemphigoid with extensive cutaneous erosions mimicking pemphigus vulgaris. ( 29930192 )
2018
5
Psoriasis vulgaris in a patient with pemphigus vulgaris on corticosteroid therapy. ( 29689136 )
2018
6
Buccal paraneoplastic pemphigus multi-resistant: Case report and review of diagnostic and therapeutic strategies. ( 29885912 )
2018
7
Comparison of ethylenediaminetetraacetic acid-treated desmoglein ELISA and conventional desmoglein ELISA in the evaluation of pemphigus vulgaris in remission. ( 29609015 )
2018
8
Paraneoplastic Pemphigus as a First Manifestation of an Intra-Abdominal Follicular Dendritic Cell Sarcoma: Rare Case and Review of the Literature. ( 29928216 )
2018
9
An Oral Disease Severity Score (ODSS) validated for use in oral pemphigus vulgaris. ( 29297927 )
2018
10
Pemphigus foliaceus and acquired haemophilia: a rare but important association with life-threatening consequences. ( 29777540 )
2018
11
Validity of the EQ-5D in pemphigus vulgaris and foliaceus patients. ( 29897626 )
2018
12
Reduced IgG anti-desmocollin autoantibody titre and concomitant improvement in a patient with pemphigus vegetans. ( 29336313 )
2018
13
Paraneoplastic pemphigus without detectable anti-plakin antibodies in a patient with non-Hodgkin lymphoma. ( 29143865 )
2018
14
Italian guidelines in pemphigus. Adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology And Venerology (EADV). ( 29860771 )
2018
15
Image Gallery: Paraneoplastic pemphigus and follicular dendritic cell sarcoma. ( 29441554 )
2018
16
Keratin Retraction and Desmoglein3 Internalization Independently Contribute to Autoantibody-Induced Cell Dissociation in Pemphigus Vulgaris. ( 29922278 )
2018
17
Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris. ( 29848521 )
2018
18
Pemphigus vegetans with the manifestations of acrodermatitis continua: A rare variant. ( 29058326 )
2018
19
Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. ( 29438767 )
2018
20
Herpetiform pemphigus with characteristic transmission electron microscopic findings of various-sized ballooning vacuoles in keratinocytes without acantholysis. ( 29573413 )
2018
21
Pemphigus Vulgaris and Radiotherapy. ( 29097073 )
2018
22
A rare presentation of congenital syphilis: Pemphigus syphiliticus in a newborn infant with extensive desquamation of the extremities. ( 29314211 )
2018
23
Pemphigus, Foliaceus ( 29763004 )
2018
24
Pemphigus herpetiformis with autoantibodies to desmocollins 1, 2 and 3. ( 29333762 )
2018
25
Reflectance confocal microscopy and optical coherence tomography for the diagnosis of bullous pemphigoid and pemphigus and surrounding sub-clinical lesions. ( 29341355 )
2018
26
Beta-adrenoceptor expression in pemphigus foliaceus. ( 29730879 )
2018
27
Auftreten einer Psoriasis vulgaris bei einem Patienten mit Pemphigus vulgaris unter Kortikosteroidtherapie. ( 29750447 )
2018
28
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab. ( 29526963 )
2018
29
Chronic Paronychia and Onychomadesis in Pemphigus Vegetans: An Unusual Presentation in a Rare Autoimmune Disease. ( 29560011 )
2018
30
Oxidative stress in patients with endemic pemphigus foliaceus and healthy subjects with anti-desmoglein 1 antibodies. ( 29723379 )
2018
31
A Case of Concomitant Pemphigus Foliaceus and Oral Pemphigus Vulgaris. ( 29340948 )
2018
32
Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceus variants and pemphigus vulgaris. ( 29489039 )
2018
33
New onset pemphigus foliaceus during pregnancy: A rare case. ( 29872686 )
2018
34
A case of pemphigus vulgaris associated with ulcerative colitis. ( 29422810 )
2018
35
Increased expression of microRNA-338-3p contributes to production of Dsg3 antibody in pemphigus vulgaris patients. ( 29749496 )
2018
36
Paraneoplastic pemphigus without antibodies to desmoglein 1 and 3. ( 29630151 )
2018
37
Study of Extrinsic Apoptotic Pathway in Oral Pemphigus Vulgaris Using TNFR 1 and FasL Immunohistochemical Markers and TUNEL Technique. ( 29854887 )
2018
38
Unusually extensive scalp ulcerations manifested in pemphigus erythematosus. ( 29469763 )
2018
39
Rituximab Treatment Of Pemphigus Foliaceus- A Retrospective Study Of 12 Patients. ( 29894702 )
2018
40
Pemphigus-A Disease of Desmosome Dysfunction Caused by Multiple Mechanisms. ( 29449846 )
2018
41
Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris. ( 29915578 )
2018
42
Lichenoid paraneoplastic pemphigus associated with follicular lymphoma without detectable autoantibodies. ( 29761536 )
2018
43
Tracing the origins of active amide group-positive drug-induced pemphigus vulgaris along the Silk Road: a case report of candesartan-induced pemphigus vulgaris and review of nonthiol drug-induced pemphigus. ( 29974942 )
2018
44
A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. ( 29408700 )
2018
45
Immunological markers as predictors of developing steroid-induced diabetes mellitus in pemphigus vulgaris patients: An observational study. ( 29702999 )
2018
46
Elevated serum eosinophil cationic protein and transforming growth factor-I+ levels in a patient with pemphigus vegetans. ( 29862541 )
2018
47
Rituximab/IVIG in pemphigus - a 10 year study with a long follow-up. ( 29889591 )
2018
48
Pathogenic IgG4 autoantibodies from endemic pemphigus foliaceus recognize a desmoglein-1 conformational epitope. ( 29307589 )
2018
49
Incidence of pemphigus vulgaris and pemphigus foliaceus in North-East Poland (Podlaskie Province) - a 15-year (2001-2015) bicentric retrospective study. ( 29873080 )
2018
50
Contact allergy caused by methylisothiazolinone in a mouthwash as the likely trigger of oral pemphigus vulgaris. ( 29726598 )
2018

Variations for Pemphigus

Expression for Pemphigus

Search GEO for disease gene expression data for Pemphigus.

Pathways for Pemphigus

GO Terms for Pemphigus

Cellular components related to Pemphigus according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.97 COL17A1 DSC1 DSC3 DSG1 DSG2 DSG3
2 cell-cell junction GO:0005911 9.73 COL17A1 DSC3 DSG1 DSG2 DSP JUP
3 intermediate filament GO:0005882 9.71 DSP DST JUP
4 ficolin-1-rich granule membrane GO:0101003 9.67 DSC1 DSG1 DSP
5 lateral plasma membrane GO:0016328 9.65 DSG1 DSG2 JUP
6 cornified envelope GO:0001533 9.65 DSC1 DSC3 DSG1 DSG2 DSG3 DSG4
7 intercalated disc GO:0014704 9.61 DSG2 DSP JUP
8 fascia adherens GO:0005916 9.51 DSP JUP
9 hemidesmosome GO:0030056 9.5 COL17A1 DST JUP
10 desmosome GO:0030057 9.32 DSC1 DSC3 DSG1 DSG2 DSG3 DSG4
11 membrane GO:0016020 10.3 ATP2C1 CD79A COL17A1 DSC1 DSC3 DSG1
12 integral component of membrane GO:0016021 10.26 ATP2C1 CD79A COL17A1 DSC1 DSC3 DSG1
13 plasma membrane GO:0005886 10.22 CD79A COL17A1 DSC1 DSC3 DSG1 DSG2
14 extracellular exosome GO:0070062 10.11 A2ML1 DSC1 DSG1 DSG2 DSG3 DSP

Biological processes related to Pemphigus according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.89 DSC1 DSG1 DSP JUP PLAUR
2 cell adhesion GO:0007155 9.86 DSC1 DSC3 DSG1 DSG2 DSG3 DSG4
3 cell-cell adhesion GO:0098609 9.73 DSG1 DSG4 DSP JUP
4 epidermis development GO:0008544 9.71 ATP2C1 COL17A1 DSP EVPL
5 keratinocyte differentiation GO:0030216 9.69 DSG4 DSP EVPL
6 keratinization GO:0031424 9.65 DSC1 DSC3 DSG1 DSG2 DSG3 DSG4
7 regulation of heart rate by cardiac conduction GO:0086091 9.63 DSG2 DSP JUP
8 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007156 9.63 DSC1 DSC3 DSG1 DSG2 DSG3 DSG4
9 maternal process involved in female pregnancy GO:0060135 9.54 DSG1 DSG2
10 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.54 DSG2 DSP JUP
11 intermediate filament cytoskeleton organization GO:0045104 9.52 DSP DST
12 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.5 DSG2 DSP JUP
13 desmosome organization GO:0002934 9.48 DSG2 DSP
14 cornification GO:0070268 9.32 DSC1 DSC3 DSG1 DSG2 DSG3 DSG4

Molecular functions related to Pemphigus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.5 DSC1 DSC3 DSG1 DSG2 DSG3 DSG4
2 cell adhesion molecule binding GO:0050839 9.33 DSG2 DSP JUP
3 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 8.8 DSG2 DSP JUP

Sources for Pemphigus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....